Analysts’ updated eps estimates for Thursday, August 10th:
Aegion Corp (NASDAQ:AEGN) had its buy rating reaffirmed by analysts at Canaccord Genuity. Canaccord Genuity currently has a $26.00 price target on the stock.
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its buy rating reissued by analysts at Chardan Capital. They currently have a $124.00 price target on the stock, down from their previous price target of $131.00.
Nivalis Therapeutics (NASDAQ:ALPN) was downgraded by analysts at Zacks Investment Research from a strong-buy rating to a hold rating. According to Zacks, “Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington. “
Blue Apron Holdings (NASDAQ:APRN) had its neutral rating reiterated by analysts at Goldman Sachs Group, Inc. (The). They currently have a $11.00 target price on the stock.
Aquinox Pharmaceuticals (NASDAQ:AQXP) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $15.00 target price on the stock. According to Zacks, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. “
Arc Logistic Partners (NYSE:ARCX) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Arc Logistics Partners LP is principally engaged in the terminalling, storage, throughput and transloading of crude oil and petroleum products. It owns, operates, develops and acquires a portfolio of complementary energy logistics assets. Arc Logistics Partners LP is based in New York. “
ArQule (NASDAQ:ARQL) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $1.00 target price on the stock. According to Zacks, “ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company’s lead ACT program, based on the E2F-1 pathway, is partnered with Roche. “
Aspen Group (OTCBB:ASPU) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Aspen Group, Inc. is an online post-secondary education company. It offers certificate programs and associate, bachelor, master, and doctoral degree programs in a range of areas, including business and organization management, education, nursing, information technology, and general studies. Aspen Group, Inc. is headquartered in Denver, Colorado. “
Anavex Life Sciences Corp. (NASDAQ:AVXL) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $3.75 price target on the stock. According to Zacks, “ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company’s proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways. “
BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “
Bio-Rad Laboratories (NYSE:BIO) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company’s products are used to separate complex chemical and biological materials, and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment offers electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation, and amplification products and services. The Clinical Diagnostics segment provides control, autoimmune, diabetes, and blood virus testing products. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. The company is headquartered in Hercules, California. “
Blue Buffalo Pet Products (NASDAQ:BUFF) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Blue Buffalo Pet Products, Inc. develops, produces, markets and sells pet food primarily in the United States. The Company’s product lines include BLUE Life Protection Formula, BLUE Wilderness, BLUE Basics, BLUE Freedom and BLUE Naturally Fresh line. It offers dry foods, wet foods as well as treats for puppies, adult dogs, senior dogs and litters for kittens, adult cats and mature cats. Blue Buffalo Pet Products, Inc. is headquartered in Wilton, Connecticut. “
The Chefs’ Warehouse (NASDAQ:CHEF) had its market perform rating reaffirmed by analysts at BMO Capital Markets. BMO Capital Markets currently has a $18.00 target price on the stock, up from their previous target price of $16.00.
Cott Corporation (NYSE:COT) (TSE:BCB) had its outperform rating reiterated by analysts at Royal Bank Of Canada. The firm currently has a $20.00 target price on the stock.
Dillard’s (NYSE:DDS) had its underweight rating reissued by analysts at J P Morgan Chase & Co. They currently have a $36.00 price target on the stock, down from their previous price target of $49.00.
Sidoti began coverage on shares of EZCORP (NASDAQ:EZPW). Sidoti issued a neutral rating on the stock.
FirstEnergy Corporation (NYSE:FE) had its buy rating reiterated by analysts at Morgan Stanley. The firm currently has a $39.00 price target on the stock, up from their previous price target of $37.00.
Twenty-First Century Fox (NASDAQ:FOXA) had its outperform rating reiterated by analysts at Royal Bank Of Canada. The firm currently has a $35.00 target price on the stock, up from their previous target price of $33.00.
Twenty-First Century Fox (NASDAQ:FOXA) had its market perform rating reaffirmed by analysts at Cowen and Company. The firm currently has a $32.00 target price on the stock, down from their previous target price of $33.00.
Galapagos NV (NASDAQ:GLPG) had its buy rating reissued by analysts at Cowen and Company.
GrubHub (NASDAQ:GRUB) had its buy rating reiterated by analysts at Canaccord Genuity. Canaccord Genuity currently has a $50.00 price target on the stock.
KemPharm (NASDAQ:KMPH) had its buy rating reiterated by analysts at Canaccord Genuity. They currently have a $7.00 target price on the stock. The analysts wrote, “Date and time of first dissemination: August 10, 2017, 16:01 ET Date and time of production: August 10, 2017, 16:01 ET Target Price / Valuation Methodology: KemPharm – KMPH Our discounted cash flow (DCF) analysis leads us to a 12-month valuation of around $7/share for KMPH, assuming a stable timeline for KemPharm’s lead products, KP415, KP201/IR and KP511/ER. Additionally, we assume a KP415 launch in 2020 and KP201/IR and KP511/ER launches in 2021. Our valuation assumes a generic launch against KP201/IR around 2031 and generic launches against KP415 and KP511/ER around 2032. This corresponds with the expiries of composition of matter patents, before any FDA term extensions, for all three products.””
Kohl’s Corporation (NYSE:KSS) was upgraded by analysts at Credit Suisse Group from an underperform rating to a neutral rating.
Kohl’s Corporation (NYSE:KSS) had its hold rating reaffirmed by analysts at Piper Jaffray Companies. The firm currently has a $37.00 target price on the stock.
Lumentum Holdings (NASDAQ:LITE) had its buy rating reissued by analysts at DA Davidson. They currently have a $83.00 price target on the stock, up from their previous price target of $77.00.
Snyder’s-Lance (NASDAQ:LNCE) had its neutral rating reiterated by analysts at UBS AG. The firm currently has a $39.00 target price on the stock, up from their previous target price of $35.00.
Manitowoc Company, Inc. (The) (NYSE:MTW) had its neutral rating reiterated by analysts at UBS AG. They currently have a $8.00 price target on the stock, up from their previous price target of $6.00.
Mylan N.V. (NASDAQ:MYL) had its outperform rating reissued by analysts at BMO Capital Markets. The firm currently has a $45.00 price target on the stock, down from their previous price target of $50.00.
Mylan N.V. (NASDAQ:MYL) had its buy rating reiterated by analysts at UBS AG. UBS AG currently has a $46.00 target price on the stock, down from their previous target price of $50.00.
Norwegian Cruise Line Holdings (NASDAQ:NCLH) had its neutral rating reiterated by analysts at UBS AG. They currently have a $60.00 target price on the stock, up from their previous target price of $51.00.
NAPCO Security Technologies (NASDAQ:NSSC) had its buy rating reiterated by analysts at Canaccord Genuity. They currently have a $12.00 target price on the stock.
Platform Specialty Products Corporation (NYSE:PAH) had its buy rating reissued by analysts at UBS AG. They currently have a $17.00 price target on the stock, up from their previous price target of $16.00.
Paylocity Holding Corporation (NASDAQ:PCTY) had its hold rating reiterated by analysts at Mizuho. The firm currently has a $45.00 price target on the stock. The analysts wrote, “We expect F4Q17 total revenue of $74-75mm (+24-25% Y/Y) vs. guidance of $73.1-74.1mm and consensus of $74mm. Recurring revenues could print around $72-73mm (up 26-28% Y/Y). For profitability, we expect adj. EBITDA of $6-7mm vs. guidance of $5.3-6.3mm and consensus of $6mm. Lastly, EPS could come in around $0.02-0.03 vs. guidance of $0.00-0.02 and consensus of $0.01.””
Raytheon (NYSE:RTN) had its buy rating reissued by analysts at Cowen and Company. The analysts wrote, “RTN’s dinner last night suggested it’s doing well on domestic captures and has.””
Southern Company (The) (NYSE:SO) had its sell rating reaffirmed by analysts at Morgan Stanley. Morgan Stanley currently has a $50.00 price target on the stock, up from their previous price target of $48.00.
US Foods Holding Corp (NASDAQ:USFD) had its outperform rating reaffirmed by analysts at Royal Bank Of Canada. They currently have a $32.00 price target on the stock.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) had its market perform rating reiterated by analysts at BMO Capital Markets. They currently have a $16.00 target price on the stock.
Vitamin Shoppe (NYSE:VSI) had its sell rating reissued by analysts at Goldman Sachs Group, Inc. (The). The firm currently has a $6.00 price target on the stock, down from their previous price target of $13.00.
Vitamin Shoppe (NYSE:VSI) had its hold rating reissued by analysts at Morgan Stanley. Morgan Stanley currently has a $8.00 target price on the stock, down from their previous target price of $14.00.
Wendy’s Company (The) (NASDAQ:WEN) had its sell rating reissued by analysts at UBS AG. The firm currently has a $13.00 price target on the stock, up from their previous price target of $12.00.
DENTSPLY SIRONA (NASDAQ:XRAY) had its buy rating reissued by analysts at Stifel Nicolaus. The firm currently has a $66.00 target price on the stock, down from their previous target price of $70.00.
